Aurora Spine received FDA 510(k) clearance to market the minimally invasive SiLO TFX MIS Sacroiliac Joint Fixation System.
SiLO TFX is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated instrumentation. SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability for bony fusion.
“We are pleased with our continued commercial momentum as we expand our footprint for providing differentiated surgical devices in the sacropelvic/sacroiliac space,” said Trent Northcutt, President and Chief Executive Officer. “We will make meaningful investments in our sales force and physician training, which we believe will enable us to further capitalize on the growth in outpatient surgery centers across the United States.”
Mr. Laszlo Garamszegi, Chief Technology Officer of Aurora Spine, added, “We are excited about this patented game-changing technology. Increased awareness of SI joint disruption as a significant contributor to back pain led us to develop a minimally invasive solution to treat the condition. It is a breakthrough for Aurora to offer a titanium version of our SiLO family of products, which offers additional fixation options to transfix the joint.”
Aurora Spine received FDA 510(k) clearance to market the minimally invasive SiLO TFX MIS Sacroiliac Joint Fixation System.
SiLO TFX is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated...
Aurora Spine received FDA 510(k) clearance to market the minimally invasive SiLO TFX MIS Sacroiliac Joint Fixation System.
SiLO TFX is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated instrumentation. SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability for bony fusion.
“We are pleased with our continued commercial momentum as we expand our footprint for providing differentiated surgical devices in the sacropelvic/sacroiliac space,” said Trent Northcutt, President and Chief Executive Officer. “We will make meaningful investments in our sales force and physician training, which we believe will enable us to further capitalize on the growth in outpatient surgery centers across the United States.”
Mr. Laszlo Garamszegi, Chief Technology Officer of Aurora Spine, added, “We are excited about this patented game-changing technology. Increased awareness of SI joint disruption as a significant contributor to back pain led us to develop a minimally invasive solution to treat the condition. It is a breakthrough for Aurora to offer a titanium version of our SiLO family of products, which offers additional fixation options to transfix the joint.”
Copy to clipboard 
